Advanced molecular platforms

Our laboratory combines multiple molecular technologies to deliver sensitive, reproducible, and phase‑appropriate results:

• qPCR / RT‑qPCR for high‑specificity quantification of nucleic acid targets

• ddPCR for ultra‑precise absolute quantification

• Multiplex PCR enabling simultaneous detection of multiple analytes

• Next‑generation sequencing (NGS) for high‑resolution genomic and transcriptomic analysis

• Viral load and pathogen quantification with industry‑leading sensitivity

These platforms are optimized for difficult matrices, low‑titer samples, and high‑complexity study designs.

Custom molecular assay development

Our scientists have deep expertise in building assays for unique targets and emerging pathogens. Capabilities include:

• De novo primer/probe design

• Optimization for sensitivity, specificity, and dynamic range

• Fit‑for‑purpose and fully validated molecular methods

• Rapid feasibility evaluation to support early program decisions

• Technology transfer for scalable clinical testing

Assays are developed with a strong understanding of regulatory expectations for molecular methods in clinical trials.

Biomarker strategy & assay development

• Biomarker consulting (mechanism-aligned selection, endpoint strategy)

• Fit-for-purpose development and full validation (small & large molecules)

• Method transfers, bridging, cross-platform harmonization

Quality, Compliance & Governance

• GxP-compliant workflows with rigorous QA oversight

• End-to-end documentation, change control, and deviation management

• Submission-ready reports and data packages designed for global regulatory expectations